Adjuvant chemotherapy of stage III colon cancer

Seminars in Oncology

Volumn 32, Issue SUPPL. 9, 2005, Pages 74-77

  Benson III, Al B ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ADJUVANT CHEMOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COLON CANCER; CONFERENCE PAPER; DIARRHEA; HAND FOOT SYNDROME; HUMAN; MICROSATELLITE INSTABILITY; MUCOSA INFLAMMATION; NEUTROPENIA; PRIORITY JOURNAL; PROGNOSIS;

EID: 30544439535     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2005.04.016     Document Type: Conference Paper

References (14)

1. D.G. Haller, P.J. Catalano, J.S. Macdonald Fluorouracil (FU), leucovorin (LV) and levamisole (LEV) adjuvant therapy for colon cancer Five-year final report of INT-0089 Proc Am Soc Clin Oncol 17 1998 (abstr 982)
2. F.L. Greene, D.L. Page, I.D. Fleming AJCC Cancer Staging Manual (Sixth Ed) 2002 Springer-Verlag New York, NY
3. S. Gill, C.L. Loprinzi, D.J. Sargent Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer Who benefits and by how much? J Clin Oncol 22 2004 1797 1806
4. T.E. Le Voyer, E.R. Sigurdson, A.L. Hanlon Colon cancer survival is associated with increasing number of lymph nodes analyzed A secondary survey of intergroup trial INT-0089 J Clin Oncol 21 2003 2912 2919
5. T. Watanabe, T.T. Wu, P.J. Catalano Molecular predictors of survival after adjuvant chemotherapy for colon cancer N Engl J Med 344 2001 1196 1206
6. C.G. Moertel, T.R. Fleming, J.S. Macdonald Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma N Engl J Med 322 1990 352 358
7. C.G. Moertel, T.R. Fleming, J.S. Macdonald Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma A final report Ann Intern Med 122 1995 321 326
8. E. Poplin, J. Benedetti, N. Estes Phase III randomized trial of bolus 5-FU/leucovorin/levamisole versus 5-FU continuous infusion/levamisole as adjuvant therapy for high risk colon cancer (SWOG 9415/INT-0153) Proc Am Soc Clin Oncol 19 2000 (abstr 931)
9. A. Saini, A.R. Norman, D. Cunningham Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer Br J Cancer 16 2003 1859 1865
10. L.B. Saltz, D. Niedzwiecki, D. Hollis Irinotecan plus fluorouracil/leucovorin (IFL) versus fluorouracil/leucovorin alone (FL) in stage III colon cancer (intergroup trial CALGB C89803) Proc Am Soc Clin Oncol 23 2004 246 (abstr 3500)
11. J. Cassidy, W. Scheithauer, J. McKendrick X-ACT study investigators Capecitabine (X) vs bolus 5-FU/leucovorin (LV) as adjuvant therapy for colon cancer (the X-ACT study) efficacy results of a phase III trial Proc Am Soc Clin Oncol 22 2004 14S (abstr 3509)
12. N. Wolmark, S. Wieand, B. Lembersky A phase III trial comparing oral UFT to FULV in stage II and III carcinoma of the colon Results of NSABP Protocol C-06 Proc Am Soc Clin Oncol 22 2004 14S (abstr 3508)
13. T. Andre, C. Boni, L. Mounedji-Boudiaf Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer N Engl J Med 350 2004 2343 2351
14. D.J. Sargent, S. Wieand, J. Benedetti Disease-free survival (DFS) vs. overall survival (OS) as a primary endpoint for adjuvant colon cancer studies: Individual patient data from 12,915 patients on 15 randomized trials Proc Am Soc Clin Oncol 23 2004 246 (abstr 3502)